Exocrine Pancreatic Insufficiency Clinical Trials

Find Exocrine Pancreatic Insufficiency Clinical Trials Near You

A Randomised, Double-Blind, Non-Inferiority Trial Comparing Microbial and Porcine Pancreatic Enzyme Replacement Therapy in Chronic Pancreatitis

Status: Recruiting
Location: See location...
Intervention Type: Other, Dietary supplement
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Background: Chronic pancreatitis (CP) is a progressive inflammatory disorder causing irreversible pancreatic damage, eventually resulting in pancreatic exocrine insufficiency (PEI). This may lead to malabsorption, malnutrition, weight loss, and impaired quality of life. Pancreatic enzyme replacement therapy (PERT) is the standard treatment for PEI and is predominantly derived from porcine sources. However, religious, ethical, dietary, and supply-related concerns highlight the need for effective non-porcine alternatives. Microbial (fungal)-based pancreatic enzymes have shown promising safety and efficacy in preliminary studies, but evidence in CP remains limited.

Objective: To compare the efficacy and safety of non-porcine microbial (fungal)-based pancreatin with standard porcine-based pancreatin in patients with PEI secondary to CP.

Methods: This investigator-initiated, randomized, double-blind, single-center, non-inferiority trial will enroll 134 adults with CP-associated PEI (defined as having a fecal elastase \<100 µg/g). After a two-week washout period, participants will be randomized 1:1 to receive either microbial-based or porcine-based pancreatin for 12 weeks. The primary outcome is the change from baseline in the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) score at 12 weeks. Secondary outcomes include nutritional status, anthropometric measures, gastrointestinal symptoms, pain scores, stool consistency, glycaemic parameters, laboratory markers, and quality of life. Discussion: This study aims to evaluate whether microbial-based pancreatin is non-inferior to porcine-based therapy and may provide a culturally acceptable and sustainable alternative for managing CP-related PEI.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:

• CP fulfilling the M-ANNHEIM criteria 11 with documented PEI (defined as fecal elastase \<100 µg/g stool on the background of morphological changes of CP).

• Pancreatic exocrine insufficiency questionnaire score (PEI-Q) \>1.4

• Willingness to undergo a 2-week wash-out period without pancreatic enzyme therapy before enrolment.

• Willing and able to provide written informed consent.

Locations
Other Locations
India
Asian Institute of Gastroenterology
RECRUITING
Hyderabad
Contact Information
Primary
Rupjyoti Talukdar, MD
rup_talukdar@yahoo.com
+917032804231
Backup
Abdul Rasheed, PharmD
Time Frame
Start Date: 2026-10-12
Estimated Completion Date: 2027-09
Participants
Target number of participants: 134
Treatments
Experimental: Non-porcine microbial based pancreatic enzyme preparation
The non-porcine microbial enzyme preparation will contain amylase (6650 DU), lipase (13000 FIP), and protease (7120 HUT, 15 SAPU, 3000 PC)
Active_comparator: Standard of care porcine pancreatic enzyme
The standard of care porcine-based enzyme preparation will contain amylase (8000 U), lipase (25000 U), and protease (1000 U)
Sponsors
Collaborators: Aalborg University
Leads: Asian Institute of Gastroenterology, India

This content was sourced from clinicaltrials.gov